EMERGING EUROPE - Growth investors should look at the Central European pharmaceuticals sector, says Baring Asset Management. According to BAM, Central European pharmaceutical companies are either supplying specialist products or breaking into the generics market. Their experience and cost advantages mean they can take market share away from the multinationals.
Klaus Bockstaller, fund manager, says: “Pharmaceutical production for the old Eastern Bloc trading region was concentrated within Hungary, Yugoslavia and countries such as Poland who focused on che...
To continue reading this article...
Join Professional Pensions
Become a Professional Pensions Lite Member today
In just a few clicks you can start your free Professional Pensions Lite membership for 12 months, providing you access to:
- Three complimentary articles per month covering the latest real-time news, analysis and opinion from the industry
- Receive important and breaking news stories via our two daily news alerts
- Hear from industry experts and other forward-thinking leaders
Are you a trustee, investment consultant or in-house pension and benefit scheme professional? You can apply for full complimentary access here
